Medtronic plc — Form 10-K Summary
Business context and reporting period
Medtronic is a global medical technology company operating in approximately 160 countries across four groups: Cardiac and Vascular, Minimally Invasive Therapies, Restorative Therapies, and Diabetes. The filing covers fiscal 2016, ended April 29, 2016—not calendar-year 2015 or a standalone 2015 fourth quarter. Fiscal 2016 had 53 weeks; fiscal 2015 had 52 weeks.
Comparability is substantially affected by the January 2015, $50 billion Covidien acquisition: fiscal 2016 includes a full year of Covidien operations, while fiscal 2015 includes results only from the acquisition date through year-end. The filing reports results in U.S. dollars.
Key financial metrics
| Metric | FY2016 | FY2015 |
|---|---|---|
| Net sales | $28.833 billion | $20.261 billion |
| Operating profit / margin | $5.291 billion / 18.4% | $3.766 billion / 18.6% |
| Net income | $3.538 billion | $2.675 billion |
| Diluted earnings per share | $2.48 | $2.41 |
| Operating cash flow | $5.218 billion | $4.902 billion |
| Capital expenditures | $1.046 billion | $571 million |
| Free cash flow (company-defined, non-GAAP) | $4.172 billion | $4.331 billion |
| Cash, cash equivalents and current investments | $12.634 billion | $19.480 billion |
| Total debt, short- and long-term | $31.240 billion | $36.186 billion |
| Working capital / current ratio | $16.435 billion / 3.3:1 | $21.671 billion / 3.4:1 |
Revenue increased 42% and net income 32% year over year, while diluted EPS rose 3%. Operating margin declined 0.2 percentage points. Management reported a $1.4 billion adverse foreign-currency translation impact on FY2016 sales. The reported increase in sales is not an organic-growth comparison because of Covidien and the extra selling week.
Group sales were $10.196 billion for Cardiac and Vascular (+9%), $9.563 billion for Minimally Invasive Therapies, $7.210 billion for Restorative Therapies (+7%), and $1.864 billion for Diabetes (+6%). The Minimally Invasive Therapies comparison is especially acquisition-distorted: FY2015 included only a partial year and FY2014 had no reported sales in this group.
Material changes and unusual items
- Interest expense, net increased to $955 million from $280 million, largely reflecting acquisition-related borrowing and the full-year effect of debt.
- Intangible-asset amortization rose to $1.931 billion from $733 million, primarily due to the full-year impact of Covidien-related intangibles. Cost of products sold also included $226 million of acquired-inventory fair-value step-up amortization.
- FY2016 included a $417 million net tax adjustment, principally a $442 million charge associated with an internal reorganization that made approximately $9.7 billion of cash and investments available for general corporate purposes, partly offset by a $25 million tax benefit.
- The company paid $3.0 billion to tender or redeem $2.7 billion of senior notes, recording a $163 million debt-extinguishment loss and an additional $20 million interest charge related to terminated interest-rate derivatives.
- Management’s non-GAAP reconciliation reported FY2016 net income of $6.228 billion and a 15.8% non-GAAP nominal tax rate, excluding specified items. These measures are not GAAP results and should be assessed alongside the reported figures.
Outlook, risks and contingencies
The filing does not provide a clear consolidated FY2017 revenue or earnings-per-share guidance figure. Management described expected product launches and market opportunities, while highlighting pricing pressure, competition, reimbursement changes and foreign-exchange exposure. It expects approximately $850 million of Covidien-related cost synergies through FY2018 and anticipated further restructuring costs to achieve them.
- Liquidity and leverage: Management said available liquidity, together with a $3.5 billion revolving credit facility, was expected to meet foreseeable working-capital needs for at least 12 months. Approximately $5 billion of cash and investments held by certain U.S.-controlled non-U.S. subsidiaries was not considered available for general corporate purposes. Net cash position, as defined by the company, was negative $18.606 billion. Debt-to-total-capital was 38%.
- Regulatory and product quality: An April 2015 FDA consent decree restricts manufacture and distribution of SynchroMed drug-infusion pumps until specified corrective actions and FDA conditions are satisfied. TYRX received an FDA Warning Letter in June 2016; the company said it was responding and taking corrective action.
- Litigation: Accrued certain litigation charges were approximately $1.0 billion at year-end. Matters include INFUSE product-liability claims and pelvic-mesh litigation; outcomes and potential ultimate costs may differ materially from recorded estimates.
- Taxes: The company disclosed substantial uncertain tax positions and ongoing tax disputes. A subsequent event disclosed in the filing says a tax-sharing dispute was resolved in May 2016, with an estimated approximately $425 million benefit expected in FY2017 first-quarter results. The Tax Court’s June 2016 opinion on the Puerto Rico income-allocation dispute generally rejected the IRS position, but final resolution remained pending.
- Other exposures: Risks include integration and realization of Covidien synergies, reimbursement and price pressure, supply interruptions, product liability, patent disputes, cybersecurity, foreign exchange, and possible tax-law changes. The filing also notes that $327 million of gross unrealized losses existed on available-for-sale debt securities with fair value of $9.7 billion.
Subsequent to year-end, Medtronic signed agreements to acquire Smith & Nephew’s gynecology business for approximately $350 million and HeartWare International for approximately $1.1 billion; both were expected to close in FY2017.
Important facts for investors to verify
- Separate acquisition-driven and extra-week effects from underlying sales growth; review constant-currency and comparable-business trends by segment.
- Track whether the company achieves the approximately $850 million synergy target by FY2018 and the associated restructuring costs.
- Monitor cash generation after capital expenditures, debt repayment, dividends and share repurchases, and confirm which overseas balances are practically available.
- Follow SynchroMed consent-decree compliance, the TYRX Warning Letter response, and developments in significant product-liability and other litigation.
- Check the final financial impact of tax disputes and the timing and realization of the expected $425 million subsequent-event tax benefit.